Company intelligence / Profile preview

EpigenTek

Farmingdale, NY, United States

Ownership: Private
Development stage: Other

Overview

EpigenTek provides commercial-scale reagents, kits, and research services to support epigenetics studies for academia, pharma, and biotechnology. They do not have therapeutics or clinical trial results, but their assays have enabled research in areas such as DNA methylation, chromatin modification, and non-coding RNA.

Modalities: Small moleculeAntibodyPeptidesProteinEnzymeNGS service (enabling platform)
Industry: Drug Discovery Services

Partnerships

Sigma-Aldrich (technology license for the Imprint ChIP Kit)EpigenCare (consumer testing, spin-off/collaboration)

Beyond the preview

Go deeper on EpigenTek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpigenTek.

Explore the full profile